In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...
Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...
The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback